Back to Blog
Metabolic
20 min read

What is Tirzepatide: Dual GIP/GLP-1 Agonist Mechanisms & Clinical Trial Results

Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, achieving superior weight loss vs. semaglutide in head-to-head trials.

Full Article Coming Soon

This article is being prepared with full inline citations and clinical evidence review. Check back soon, or browse our protocol library for dosing information.

Browse Protocols

Research & Educational Use Only: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.